Anti-Myelin Oligodendrocyte Glycoprotein (MOG), Serum
Use
Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis; diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy; diagnosis of neuromyelitis optica (NMO); distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease; diagnosis of ADEM; prediction of a relapsing disease course
Special Instructions
Not provided.
Limitations
MOG IgG antibody titers may assist in monitoring disease course and prognosis, but their role is imperfect. Antibody titers may increase but may not be predictive of relapses or attacks. MOG IgG antibodies may become undetectable with immunosuppression, but this does not necessarily indicate clinical response. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.
Methodology
Immunoassay (Immunofluorescence (IFA))
Biomarkers
MOG Antibody
Protein
LOINC Codes
- 91545-4 - MOG Ab Ser Ql CBA IFA
- 91545-4 - MOG Ab Ser Ql CBA IFA
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Serum from a red-top tube, gel-barrier tube, or serum transfer tube
Storage Instructions
Room temperature
Causes for Rejection
Gross hemolysis; grossly lipemic
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant